Novo Nordisk Disease areas Science & technology Partnering Sustainable business Careers About us Our products Patients Investors News & media Healthcare professionals Contact us Read our company announcement See our progress Protect your health Latest news {{'2025-12-22T22:50:36Z' | dateFormatFilter}} Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management Read more {{'2025-12-18T13:08:27Z' | dateFormatFilter}} Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Read more {{'2025-12-12T13:57:33Z' | dateFormatFilter}} Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss Read more News archive Investors Share price {{priceData.date}} {{priceData.time}} {{priceData.currentPrice}} {{priceData.currency}} Go to stock watch {{priceData.change}} {{priceData.currency}} Quick links Conference calls & other events Visit Capital Markets day Stock information Press releases and company announcements R&D Pipeline Annual Report Annual Report 2024 Download Annual Report NOVO NORDISK HQ Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page Helpful links Report a side effect Patient help Supplier help Product list Contact us Our Purpose - Code of conduct ESG reporting Novo Nordisk Foundation Follow us Social media community guidelines LinkedIn YouTube Facebook X (Twitter) Instagram TikTok Find your local office Select location © 2025 Novo Nordisk A/S Data Privacy Cookie policy Cookie settings change